Tirzepatide

Tirzepatide is a synthetic dual GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptor agonist — and one of the most advanced peptide compounds available for metabolic research. By simultaneously targeting two distinct incretin receptors, Tirzepatide enables a broader and more nuanced investigation of metabolic signaling pathways than single-receptor agonists, making it a benchmark compound for studying energy homeostasis, insulin secretion, and lipid regulation.

Dual GIP & GLP-1 receptor agonist — simultaneous activation of two incretin pathways for deeper research insights
Advanced metabolic signaling — studied for insulin secretion, glucose homeostasis & energy balance modulation
Superior receptor coverage — broader experimental results vs. single-receptor GLP-1 agonists
≥99% purity — HPLC-verified, every batch
Flexible dosing — TR5 to TR60, matched to your protocol

Main Benefits:

• Dual incretin receptor activation — GIP & GLP-1 pathways studied simultaneously
• Investigated for enhanced insulin secretion and beta-cell function vs. single agonists
• Supports glucose homeostasis and glycemic regulation research models
• Studied for appetite suppression, energy intake reduction & body weight regulation
• Lyophilized format — stable, consistent reconstitution and extended shelf life

For Research Use Only.